United States: Five Important Themes To Watch In The Reform Of FDA's Off-Label Communications Policy

As we've previously reported, FDA has recently been forced to reexamine its legal position and enforcement policies related to drug and device manufacturers' off-label communications. Although the Agency has for years resisted calls to loosen its long-standing prohibitions on the off-label promotion of unapproved products, it has simultaneously recognized that truthful and non-misleading scientific or medical information coming from manufacturers about their own drug, biologic, and device products plays an important role in the U.S. health care system. This has especially been true in a climate where individual products are becoming more complex; precision medicine approaches to treating disease are gaining ground in clinical practice; and the health system is evolving into one more focused on outcomes and value-based arrangements between entities. The expansion of First Amendment commercial speech principles by the courts over the past decade and lawsuits against FDA also have pushed the Agency to move towards the potential reform of its existing off-label policies.

FDA recently held a highly anticipated public hearing to allow different stakeholders to express their distinct viewpoints regarding the appropriate regulatory approach to manufacturers' communications about off-label uses for their marketed products. Over the course of those two days, the panel of FDA officials convened for the event (as well as those of us in attendance or watching via webcast) heard perspectives from representatives of drug and device manufacturers, health care professionals, patients and caregivers, patient advocacy groups, research institutions, insurers and other payors. Although the presentations and discussions raised many more questions than it provided answers, we took away 5 recurring themes from this hearing on off-label communications.

Our "Top 5 Themes" of the Off-Label Hearing

  1. Different Rules Are Needed for Different Circumstances. Companies and trade groups argued that FDA cannot maintain a "one-size-fits-all" policy for two main reasons – not all communications are created equal, and not all products have the same risks associated with off-label use. For example, medical device manufacturers advocated for their own policy approach in light of the training and ongoing technical support they provide to users of complex medical devices. Stakeholders asked the Agency to delineate the permissible scope of each particular type of communication and to define those "safe harbors" clearly and with sufficient detail to eliminate the uncertainty that currently abounds when it comes to certain types of truthful and non-misleading scientific exchange. Allowing manufacturers to engage in narrowly defined communications that are put into proper context with appropriate disclaimers, certifications, or other protections in place (like the current framework for providing off-label reprints to health care professionals) seemed to have numerous supporters. Other suggested approaches included the development of an adverse event reporting system for off-label uses only.
  2. Off-Label Information Should Be Shared with Health Plans and Payors. Manufacturer entities, as well as health plans and payors who also addressed the panel, urged FDA to create a safe harbor that would permit product developers to share information with payors about their products before approval, while a new or supplemental application is undergoing FDA review. Harms to patients can accrue when an insurer does not have enough clinical data to make a coverage decision about a medically accepted off-label use for a product, because often the product manufacturer is the best source of such clinical information given its comprehensive monitoring of its product's risks and benefits. Representatives of both manufacturers and health plans pointed out that health plans and payors are extremely sophisticated recipients of data and information, and as such would be appropriate recipients of off-label information.
  3. Lack of Drug Development Specific to Vulnerable Populations Encourages Off-Label Uses, and Increased Communication Would Protect Those Patients. Many off-label uses for approved products are a consequence of the lack of drugs developed specifically for pediatric populations or for certain rare disease indications. A patient advocacy group explained that pediatric cancer patients routinely receive off-label treatments with drugs, biologics, and medical devices because no cancer treatment is specifically approved by FDA for pediatric use. And physicians pointed out that many drugs are useful in treating ophthalmological diseases and conditions, even though FDA has not approved such indications, and cutting off the flow of scientific data to treating physicians will restrict the ability of doctors to provide effective treatments. Clinicians and other practitioners treating these uniquely vulnerable populations desire easy access to relevant, legitimate data about risks and alternative dosing regimens, which, again, product manufacturers may be in the best position to provide. However, the participants making this argument agreed that manufacturers must be required to provide some certification or statement about the degree of reliability of such data.
  4. Adverse Events Associated with Off-Label Uses May Be Tempered with More Off-Label Communications. As FDA Commissioner Califf noted in his remarks at the start of the hearing, off-label uses are typically associated with more adverse events than approved uses for the same drug. Patients as well as some patient advocacy groups strongly opposed any loosening of off-label communication rules, in part due to these increased safety risks and specific examples of serious patient harms or death as a consequence of an unapproved use. Other patient advocacy groups, however, argued that off-label communications should be permitted to expand legitimate treatment options but with certain patient protections, such as informed consent from the patient and the existence of sufficient literature supporting the off-label treatment's safety and effectiveness. The unanswerable question underpinning these arguments is: Would there be fewer, or less serious, adverse experiences associated with off-label use if clinicians were better informed about the parameters of an off-label use.
  5. Off-Label Communications Are Valuable in Precision Medicine. The advancement and success of precision medicine – where knowledge of disease subtypes and a patient's specific genetic and metabolic profile is used to tailor treatment towards the best possible outcome – could be directly impacted by manufacturers' ability to share information with other health care stakeholders. Developers of genetic tests and screening devices explained that new evidence and uses for those tests are constantly being published in the medical literature and such evidence should be available to guide clinicians when they are making treatment or dosing decisions for patients.

Persons who may want to watch the archived webcast of the event or review the eventual transcript can access those materials on FDA's website here.

This informal hearing was the beginning of an information-gathering phase for FDA, which will continue through January 9, 2017 – it is accepting written comments on the topic until that date and we recommend that all affected stakeholders submit their feedback to the Agency (Docket Number FDA-2016-N-1149). It remains to be seen what actions FDA will take in response to the increasing public pressure to reform its policies related to off-label communications.

Will FDA proceed in a stepwise fashion, as urged by some members of industry, to permit certain communications with payors first, then move on to more complicated and controversial circumstances? Will the Agency immediately issue a draft guidance to explain how it is going to integrate First Amendment concerns into its policies on manufacturer communications? While we don't yet know which approach FDA will take, rest assured that we will be watching FDA's next steps closely and will report back on any future developments in this area.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions